Detalles de la búsqueda
1.
Effectiveness and safety of granulocyte colony-stimulating factor priming regimen for acute myeloid leukemia: A systematic review and meta-analysis of the Clinical Practice Guideline for the use of G-CSF 2022 from the Japan Society of Clinical Oncology.
Int J Clin Oncol;
2024 May 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-38755516
2.
Concomitant osimertinib and antituberculosis therapy in an elderly patient with EGFR-mutated lung cancer and pulmonary tuberculosis: A case report.
Thorac Cancer;
2024 May 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-38698706
3.
Osimertinib is associated with improved outcomes in pre-treated non-small cell lung cancer leptomeningeal metastases: A systematic review and meta-analysiss.
Heliyon;
10(9): e29668, 2024 May 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-38698967
4.
Therapeutic use of granulocyte colony-stimulating factor (G-CSF) in patients with febrile neutropenia: a comprehensive systematic review for clinical practice guidelines for the use of G-CSF 2022 from the Japan Society of Clinical Oncology.
Int J Clin Oncol;
2024 May 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-38696053
5.
Effectiveness of G-CSF in chemotherapy for digestive system tumors: a systematic review of the Clinical Practice Guidelines for the Use of G-CSF 2022 delineated by the Japan Society of Clinical Oncology.
Int J Clin Oncol;
2024 Apr 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-38578596
6.
Comparison between a single dose of PEG G-CSF and multiple doses of non-PEG G-CSF: a systematic review and meta-analysis from Clinical Practice Guidelines for the use of G-CSF 2022.
Int J Clin Oncol;
2024 Apr 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-38649648
7.
Pulmonary function and chest CT abnormalities 3 months after discharge from COVID-19, 2020-2021: A nation-wide multicenter prospective cohort study from the Japanese respiratory society.
Respir Investig;
62(4): 572-579, 2024 Apr 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-38669898
8.
Effectiveness and safety of primary prophylaxis of granulocyte colony-stimulating factor during dose-dense chemotherapy for urothelial cancer: Clinical Practice Guidelines for the Use of G-CSF 2022.
Int J Clin Oncol;
29(5): 545-550, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38517658
9.
Effectiveness and safety of primary prophylaxis of G-CSF during chemotherapy for prostate cancer, Japanese clinical guideline for appropriate use of G-CSF: clinical practice guidelines for the use of G-CSF 2022.
Int J Clin Oncol;
29(5): 559-563, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38538963
10.
Effectiveness and safety of primary prophylaxis with G-CSF after induction therapy for acute myeloid leukemia: a systematic review and meta-analysis of the clinical practice guidelines for the use of G-CSF 2022 from the Japan society of clinical oncology.
Int J Clin Oncol;
29(5): 535-544, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38494578
11.
Optimal timing of prophylactic pegylated G-CSF after chemotherapy administration for patients with cancer: a systematic review and meta-analysis from Clinical Practice Guidelines for the use of G-CSF 2022.
Int J Clin Oncol;
29(5): 551-558, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38526621
12.
A Prompt Diagnosis and Treatment of a Case of Nuclear Protein of the Testis Carcinoma Characterized by a Bronchial Lesion and High Serum Alpha-fetoprotein Level Following Genomic Testing.
Intern Med;
2024 Feb 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-38403772
13.
Effectiveness and safety of primary prophylaxis with G-CSF for lung cancer: a systematic review and meta-analysis to develop clinical practice guidelines for the use of G-CSF 2022.
Int J Clin Oncol;
29(4): 355-362, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38353907
14.
Efficacy and Safety of Re-administration of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKI) After EGFR-TKI-Induced Interstitial Lung Disease (CS-Lung-005).
Lung;
202(1): 63-72, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-38265672
15.
Impacts of probiotics on the efficacies of immune checkpoint inhibitors with or without chemotherapy for patients with advanced non-small-cell lung cancer.
Int J Cancer;
154(9): 1607-1615, 2024 May 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38196128
16.
Prospective observational study to explore genes and proteins predicting efficacy and safety of brigatinib for ALK-gene rearranged non-small-cell lung cancer: study protocol for ABRAID study (WJOG11919L).
Ther Adv Med Oncol;
16: 17588359231225046, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38282663
17.
CDK4/6 signaling attenuates the effect of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer.
Transl Lung Cancer Res;
12(10): 2098-2112, 2023 Oct 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-38025818
18.
A randomized controlled trial of teprenone in terms of preventing worsening of COVID-19 infection.
PLoS One;
18(10): e0287501, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37883347
19.
Severe Cytokine Release Syndrome and Immune Effector Cell-associated Neurotoxicity Syndrome in a Man Receiving Immune Checkpoint Inhibitors for Lung Cancer: A Case Report.
Intern Med;
2023 Sep 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-37722894
20.
Efficacy of gilteritinib in comparison with alectinib for the treatment of ALK-rearranged non-small cell lung cancer.
Cancer Sci;
114(11): 4343-4354, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37715310